<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974025</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00029464</org_study_id>
    <nct_id>NCT00974025</nct_id>
  </id_info>
  <brief_title>Impact of Vitamin C on Endothelial Function and Exercise Capacity in Fontan-Palliated Patients</brief_title>
  <official_title>Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Griese-Hutchinson Champions for Children's Hearts Investigator Award</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, investigators will evaluate the effect of vitamin C on endothelial function,
      exercise tolerance and quality of life in patients with a single ventricle who have been
      palliated to Fontan physiology. The hypothesis is that vitamin C will result in improved
      exercise tolerance and endothelial function in patients who have undergone the Fontan
      operation, compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent evidence suggests that after Fontan operation, single ventricle patients have impaired
      function of the vascular endothelium due in part to abnormalities in nitric oxide signaling.
      Endothelial dysfunction may contribute to the development of congestive heart failure and
      exercise intolerance that have been well-documented in Fontan patients. Therapeutic
      interventions to improve endothelial function in adults with heart failure have mainly
      focused on increasing the synthesis or decreasing the degradation of nitric oxide. We propose
      a randomized, prospective, placebo-controlled trial of vitamin C, an antioxidant that
      protects NO deactivation, in subjects with single ventricular anatomy after Fontan
      palliation. The specific aims of this study are to compare NO signaling, endothelial function
      and exercise capacity in Fontan subjects to that of a control group that is frequency-matched
      to case subjects by age and sex, and to assess NO signaling, endothelial function and
      exercise capacity in Fontan subjects after 4 weeks of oral vitamin C (or placebo) therapy.
      These results have particular importance because improving the endothelial response in Fontan
      patients has the potential to reduce the risk of developing congestive heart failure and
      improve exercise capacity. Furthermore, assessing endothelial function and the effects of
      therapies aimed at improving vascular health may be generalizable to many other chronic
      pediatric conditions associated with increased cardiovascular risk such as obesity, diabetes
      mellitus, and hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peak oxygen consumption (from baseline to post-study drug testing)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen Pulse</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Work</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endo-PAT score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Framingham Modified Endothelial Function Score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PedsQL 4.0 - quality of life assessment</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BNP</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Fontan Procedure</condition>
  <condition>Hypoplastic Left Heart Syndrome</condition>
  <condition>Tricuspid Atresia</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose Vitamin C in 4 age-based doses will be given in two-daily doses for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given in two-daily doses for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>High-dose Vitamin C will be administered in 4 age-based dosing groups</description>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered twice daily for four weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  8-25 years of age

          -  Fontan-palliated patient

        Exclusion Criteria:

          -  New York Heart Association (NYHA) classes III or IV

          -  Diabetes mellitus

          -  Family history of premature coronary artery disease

          -  Use of Sildenafil or other pulmonary artery vasodilators

          -  Prior cardiac arrest (outside the first 24-hours postoperatively)

          -  Life-threatening dysrhythmias

          -  Severe ventricular dysfunction

          -  Severe AV valve regurgitation

          -  Pregnancy

          -  Severe renal or hepatic impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R Charpie, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bryan H Goldstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Goldstein BH, Golbus JR, Sandelin AM, Warnke N, Gooding L, King KK, Donohue JE, Gurney JG, Goldberg CS, Rocchini AP, Charpie JR. Usefulness of peripheral vascular function to predict functional health status in patients with Fontan circulation. Am J Cardiol. 2011 Aug 1;108(3):428-34. doi: 10.1016/j.amjcard.2011.03.064. Epub 2011 May 19.</citation>
    <PMID>21600541</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>John R. Charpie</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
    <mesh_term>Tricuspid Atresia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

